Analyst Price Targets — KURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 2:14 pm | — | Leerink Partners | $20.00 | $9.03 | TheFly | Kura Oncology price target lowered to $20 from $25 at Leerink |
| November 24, 2025 11:29 am | Etzer Darout | Barclays | $28.00 | $11.17 | TheFly | Kura Oncology price target raised to $28 from $11 at Barclays |
| November 14, 2025 1:01 pm | — | Wedbush | $38.00 | $11.57 | TheFly | Kura Oncology price target raised to $38 from $36 at Wedbush |
| November 14, 2025 11:53 am | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.78 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA) |
| March 6, 2025 12:21 pm | — | UBS | $14.00 | $7.70 | TheFly | Kura Oncology price target lowered to $14 from $27 at UBS |
| November 22, 2024 6:33 pm | Bradley Canino | Stifel Nicolaus | $11.00 | $10.80 | StreetInsider | Kura Oncology (KURA) PT Lowered to $11 at Stifel |
| October 24, 2024 4:03 am | David Dai | UBS | $27.00 | $17.02 | StreetInsider | UBS Starts Kura Oncology (KURA) at Buy |
| October 14, 2024 12:36 am | Bradley Canino | Stifel Nicolaus | $19.00 | $18.58 | StreetInsider | Stifel Downgrades Kura Oncology (KURA) to Hold |
| June 25, 2024 6:44 am | Joseph Pantginis | H.C. Wainwright | $32.00 | $21.08 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA) |
| May 23, 2024 4:03 pm | Bradley Canino | Stifel Nicolaus | $28.00 | $21.43 | StreetInsider | Stifel Reiterates Buy Rating on Kura Oncology (KURA) |
Latest News for KURA
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m.…
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences:
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to…
Kura Oncology is upgraded from buy to strong buy, driven by a compelling valuation reset and robust cash position. Komzifti's FDA approval for relapsed/refractory NPM1-mutated AML is de-risked; the true equity upside lies in frontline AML expansion. Recent data show high remission rates and a favorable safety profile for Komzifti in frontline combinations, supporting the strategic thesis.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KURA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.